Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.

Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.

BACKGROUND:Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease with a poor prognosis. Pirfenidone is the first antifibrotic agent to be approved for IPF-treatment as it is able to slow down disease progression. However, there is no curative treatment other than lung transplantation. Be...

Full description

Bibliographic Details
Main Authors: Martina Korfei, Daniel Stelmaszek, BreAnne MacKenzie, Sylwia Skwarna, Shashipavan Chillappagari, Anna C Bach, Clemens Ruppert, Shigeki Saito, Poornima Mahavadi, Walter Klepetko, Ludger Fink, Werner Seeger, Joseph A Lasky, Soni S Pullamsetti, Oliver H Krämer, Andreas Guenther
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC6258535?pdf=render

Similar Items

Similar Items